Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Combined Hepatitis A and B vaccine · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Combined Hepatitis A and B vaccine | BIOLOGICAL | - |
Inclusion Criteria: * Subjects who received GSK Biologicals' combined hepatitis A and B vaccine in the primary study (HAB-082). Subjects were aged 12 to 15 years at the time of the first vaccination.
Top 6 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Viread, Tenofovir alafenamide |
| Vir Biotechnology, Inc. | VIR | 6 | PHASE3 | Tobevibart, Elebsiran |
| Bausch Health Companies Inc. | BHC | 1 | PHASE3 | Larsucosterol |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Daplusiran/Tomligisiran, Bepirovirsen |
| Aligos Therapeutics, Inc. | ALGS | 1 | PHASE2 | ALG-000184 |
| Precision BioSciences, Inc. | DTIL | 2 | PHASE1 | PBGENE-HBV |
The combined hepatitis A and B vaccine is an investigational vaccine developed by GSK plc that is designed to protect against both hepatitis A and hepatitis B in a single product. It is being studied in a Phase 3 clinical program, with hepatitis B listed as its primary indication and hepatitis A also evaluated in its trials.
The combined hepatitis A and B vaccine is intended for immunization against hepatitis A and hepatitis B virus infection. GSK plc is developing it as a single vaccine covering both viruses, and its completed Phase 3 study enrolled healthy volunteers aged 12 years and older in Australia who received the combined vaccine.
GSK plc, which trades under the ticker GSK, is the developer of the combined hepatitis A and B vaccine. The company sponsored the Phase 3 study of the vaccine, and GSK holds the program as part of its infectious disease vaccine portfolio.
The combined hepatitis A and B vaccine is in Phase 3 development. It is an investigational vaccine and is not described as approved. One Phase 3 trial has been completed, and no trials are currently listed as active for this program.
The combined hepatitis A and B vaccine has been studied in one completed Phase 3 trial, NCT00197171, titled Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine. It enrolled 143 participants in Australia, aged 12 years and older, including healthy volunteers.
Yes, the Phase 3 trial of the combined hepatitis A and B vaccine, NCT00197171, was randomized. It was not double blinded and used an uncontrolled design, and it enrolled 143 participants. The study has been completed and compared two vaccination schedules of the combined vaccine.